Charles S. Cotropia – CEO and Chairman of the Board

Mr. Cotropia holds a Bachelor of Science degree with honors in Aerospace Engineering from the University of Texas at Austin and a Juris Doctorate Degree from Cornell University. He is a member of the Texas Bar Association and has served as a Member of the Board of Directors of the Dallas Bar Association. He is licensed to practice law in Federal District and Texas State courts and before the United States Patent and Trademark Office.

Prior to his current position as CEO and Board Chairman of Enzolytics, Mr. Cotropia served as CEO of BioClonetics Immunotherapeutics, Inc. from its formation in 2009 until the recent acquisition of BioClonetics by Enzolytics.

From 1973 until 2015, Mr. Cotropia also practiced law, specializing in the intellectual property field. During that period, he served as a partner in the law firm Sidley Austin LLP in its Dallas office. As an intellectual property lawyer for over 43 years, he handled cases in the areas of patents, trademarks, trade dress, unfair competition, and copyrights. As a lawyer, he served as lead counsel in patent, trademark, trade dress, and copyright disputes litigated in Federal and State Courts and the United States Patent and Trademark Office. During his legal career, Mr. Cotropia represented clients in the diverse areas of biotech, aerospace, electronics, the Internet, commercial products, and oil and gas equipment and processes.

Harry H. Zhabilov – CSO and Director

Mr. Zhabilov is Chief Scientific Officer of Enzolytics, Inc. He also serves as President & Chief Scientific Officer at Immunotech Laboratories, Inc. He is a Member of the American Institute of Chemical Engineers and a Member of the American Chemical Society. Mr. Zhabilov previously served as Executive Vice President at VG Life Sciences, Inc., Vice Chairman, Secretary & Chief Science Officer at International Technology Systems, Inc., and as Research Scientist at Bulgarian Academy of the Sciences.

Mr. Zhabilov holds a Master’s Degree from the University of Chemical Technology and Metallurgy in Sofia, Bulgaria. He is also a Member of the American Chemical Society and a Member of the American Institute of Chemical Engineers. Mr. Zhabilov served as Chief Scientific Officer for GXP Biopharm, Inc., and Vice President of Research and Development for Viral Genetics, Inc.

Mr. Zhabilov has extensive experience in protein isolation and purification in immunochemistry and biochemistry, along with experience with therapeutic proteins used to treat HIV and cancer. Mr. Zhabilov also has experience in the preparation of applications for a nutraceutical compound/supplement submitted to the FDA. He is also the inventor named in several U.S. patents covering technology related to the immunotherapy of HIV and cancer and an immune enhancer based on the IPF (Inactivated Pepsin Fragment) platform. Mr. Zhabilov has also participated in the management of several clinical trials utilizing therapeutic proteins.

Joseph P. Cotropia, MD – Chief Medical Officer and Director

Dr. Cotropia holds a Medicine Degree from the Univ. of Texas Southwestern Medical School, a Master of Science Degree in Physiological Chemistry from the University of Wisconsin at Madison, Wis., and a Bachelor of Science Degree from the University of Texas at Austin, Texas.

He has taught as an Assistant Professor of Immunology at the University of Texas M.D. Anderson Hospital and Tumor Institute in Houston, Texas, served as an Internal Medicine Intern at Presbyterian Hospital Dallas, Texas, and completed his internal medicine residency at the Central Texas Medical Foundation, Brackenridge Hospital in Austin, Texas.

Dr. Cotropia has worked previously at the M.D. Anderson Cancer Center and the Food and Drug Administration Center, and the Food and Drug Administration Center for Biologics Evaluation and Research (CBER) where he had hands-on experience with immunotherapeutic biotechnology platforms directly related to monoclonal antibodies. Dr. Cotropia is the creator of the Company’s fully human anti-HIV monoclonal antibodies and the Company’s proprietary methodology for producing monoclonal antibodies targeting numerous infectious diseases.

He has clinical experience as a staff physician at the University of Pennsylvania, has worked in cell biology at the Center for Biologics Evaluation and Research Division at the Food and Drug Administration in Bethesda, Maryland, and has further clinical experience as a physician at the University of Texas Health Center.

Gaurav Chandra, MD – Chief Operating Officer and Director

Dr. Gaurav Chandra has a Doctor of Medicine Degree from Albert Einstein College of Medicine, Montefiore, NY, a Bachelor of Medicine degree from Kasturba Medical College, Manipal India, and a Masters in Business Administration Degree from the University of Colorado, Denver, Colorado.

He is a trained surgeon with a Fellowship in Burn Surgery and Critical Care at the University of Colorado, Denver, Colorado. He has extensive experience in Clinical Research in Immunology and Infectious Diseases. His scientific contributions and advancements have been recognized globally. He also has vast experience with taking ideas all the way from basic research in the lab to clinical applications. His experience also extends to designing and conducting Pre-Clinical and Clinical Trials for Drug Development.

He brings experience in applying Artificial Intelligence to the field of biomedical therapeutic development and continues to lead the integration of Artificial Intelligence into the Company’s technology for the creation of multiple potent therapeutic Monoclonal Antibodies.

He has global experience serving as a strategic advisor to senior executives of private equity firms, biopharma companies, and healthcare systems to implement strategic goals.

Ronald Moss, MD – Scientific Advisor

Dr. Moss has a Doctor of Medicine Degree from the Chicago Medical School, Chicago, IL, and a Bachelor of Arts degree from SUNY at Stony Brook, NY. His post-graduate training includes courses at the American Association of Immunologists Advanced Immunology Course, HIV Primary Care Mini-Residency Program, Owen Clinic, University of California at San Diego; Allergy and Immunology Fellowship, Clinical Associate in Allergy and Clinical Immunology, Laboratory of Clinical Investigation, NIAID, National Institute of Health, Bethesda MD.

Dr. Moss completed his medical residency in Pediatrics (Research Track) and Assistant Clinical Institute at SUNY in Stony Brook Department of Pediatrics, Stony Brook, NY.

He serves on many corporate boards and has held officer positions in several biotech companies, including:

  • Adamis Pharmaceuticals, San Diego, CA, March 2017-Present, Chief Medical Officer
  • Ansun Biopharma Inc., San Diego, CA
  • Nexbio Inc, San Diego, CA
  • Vical Inc., San Diego, CA
  • Telos Pharmaceuticals, San Diego, CA
  • Merck & Co. Inc., West Point, PA
  • The Immune Response Corp., Carlsbad, CA

He has also taught at the UCSD Medical Center, Division of Allergy/Immunology, as Associate Clinical Professor from 1994 to the present.